Pharmaceuticals Market Research Reports & Industry Analysis

Publications found: 36,694

Sort by:

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018

US$ 3,500.00

... Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 66 pages

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018

US$ 3,500.00

... Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 53 pages

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2018

US$ 3,500.00

... Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 115 pages

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 31 pages

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2018

US$ 3,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape Develop and ...

March 2018 66 pages

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape Develop and design ...

March 2018 81 pages

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H1 2018

US$ 3,500.00

... Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 74 pages

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H1 2018

US$ 3,500.00

... reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 47 pages

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H1 2018

US$ 3,500.00

... Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 69 pages

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H1 2018

US$ 3,500.00

... Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 66 pages

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018

US$ 3,500.00

... Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 138 pages

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape Develop and design ...

March 2018 120 pages

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H1 2018

US$ 3,500.00

... Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 88 pages

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H1 2018

US$ 3,500.00

... Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 36 pages

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape Develop and ...

March 2018 27 pages

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape Develop and design ...

March 2018 51 pages

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2018

US$ 3,500.00

... Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 60 pages

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2018

US$ 3,500.00

... Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 64 pages

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H1 2018

US$ 3,500.00

... Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 58 pages

Anti-Epileptic Drugs: Global Markets to 2022

US$ 2,750.00

... anti-epileptic drugs market Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022 Identification of segments ...

March 2018 161 pages

Drugs for Infertility: Global Markets to 2022

US$ 2,750.00

... women and pharmaceutical drugs that enhance the reproductive fertility Insight into the type of infertility drugs, i.e., anti-estrogens and gonadotropins Profiles of major companies in the market, including Bayer ...

March 2018 167 pages

2018 U.S. Drugs, health aids, beauty aids sold through Other specialty food stores-Product & Retail Report

US$ 199.00

The 2018 U.S. Drugs, health aids, beauty aids sold through Other specialty food stores-Product & Retail Report, ... . The report features 2018 current and 2019 forecast estimates on the sales of Drugs, health aids, beauty aids nationally and for all 50 U.S. States and up to 900 metro ...

March 2018 93 pages

Global Generics Industry Profile & Value Chain Analysis

US$ 495.00

Global Generics Industry Profile & Value Chain Analysis SUMMARY Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value ... is dominated by major international pharmaceutical companies, but specialist generic companies exist in the market, ...

March 2018 45 pages

2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Electronic shopping-Product & Retail Report

US$ 199.00

The 2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Electronic shopping-Product & Retail Report, ... report features 2018 current and 2019 forecast estimates on the sales of Drugs, health aids, beauty aids, incl cosmetics nationally and for all 50 U.S. States and up to 900 ...

March 2018 93 pages

2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Other clothing stores-Product & Retail Report

US$ 199.00

The 2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Other clothing stores-Product & Retail ... report features 2018 current and 2019 forecast estimates on the sales of Drugs, health aids, beauty aids, incl cosmetics nationally and for all 50 U.S. States and up to 900 ...

March 2018 93 pages

2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Other gasoline stations-Product & Retail Report

US$ 199.00

The 2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Other gasoline stations-Product & Retail ... report features 2018 current and 2019 forecast estimates on the sales of Drugs, health aids, beauty aids, incl cosmetics nationally and for all 50 U.S. States and up to 900 ...

March 2018 93 pages

2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Other home furnishings stores-Product & Retail Report

US$ 199.00

The 2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Other home furnishings stores-Product & ... report features 2018 current and 2019 forecast estimates on the sales of Drugs, health aids, beauty aids, incl cosmetics nationally and for all 50 U.S. States and up to 900 ...

March 2018 93 pages

2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Sporting goods stores-Product & Retail Report

US$ 199.00

The 2018 U.S. Drugs, health aids, beauty aids, incl cosmetics sold through Sporting goods stores-Product & Retail ... report features 2018 current and 2019 forecast estimates on the sales of Drugs, health aids, beauty aids, incl cosmetics nationally and for all 50 U.S. States and up to 900 ...

March 2018 93 pages

Resistant Hypertension: Drug Development Pipeline Study, H1 2018

US$ 806.00

... . The most comprehensive pipeline review “Resistant Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Resistant Hypertension pipeline drugs. Current status of all the drugs in the Resistant Hypertension pipeline is provided in the ...

March 2018 28 pages

Portal Hypertension: Drug Development Pipeline Study, H1 2018

US$ 806.00

... . The most comprehensive pipeline review “Portal Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Portal Hypertension pipeline drugs. Current status of all the drugs in the Portal Hypertension pipeline is provided in the ...

March 2018 31 pages

Ocular Hypertension: Drug Development Pipeline Study, H1 2018

US$ 806.00

... . The most comprehensive pipeline review “Ocular Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Ocular Hypertension pipeline drugs. Current status of all the drugs in the Ocular Hypertension pipeline is provided in the ...

March 2018 61 pages

Cancer Cachexia: Drug Development Pipeline Study, H1 2018

US$ 806.00

... . The most comprehensive pipeline review “Cancer Cachexia- Drug Development Pipeline Study” provides in-depth analysis and update information on Cancer Cachexia pipeline drugs. Current status of all the drugs in the Cancer Cachexia pipeline is provided in the ...

March 2018 47 pages

Bone Fracture - Pipeline Review, H1 2018

US$ 2,000.00

... releases. The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

March 2018 105 pages

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018

US$ 3,500.00

... Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 71 pages

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2018

US$ 3,500.00

... Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 62 pages

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018

US$ 2,000.00

... . The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

March 2018 55 pages

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2018

US$ 3,500.00

... 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 69 pages

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H1 2018

US$ 3,500.00

... Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 106 pages

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H1 2018

US$ 3,500.00

... Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 48 pages

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) development ...

March 2018 75 pages

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H1 2018

US$ 3,500.00

... High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 40 pages

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape Develop and design ...

March 2018 55 pages

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H1 2018

US$ 3,500.00

... Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 60 pages

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Pipeline Review, H1 2018

US$ 3,500.00

... , this report also reviews key players involved in Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics development with respective active and ...

March 2018 56 pages

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H1 2018

US$ 3,500.00

... , this report also reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics development with respective active and ...

March 2018 68 pages

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) development landscape Develop ...

March 2018 29 pages

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018

US$ 3,500.00

... Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 66 pages

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H1 2018

US$ 3,500.00

... Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 59 pages

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pipeline Review, H1 2018

US$ 3,500.00

... Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 38 pages

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) development landscape ...

March 2018 43 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

Discount Offer from GMD Research

Special Offer from MP Advisors

Special Offer on Therapy Class R...